Uterine fibroid procedures: hidden costs and financial traps

A retrospective analysis of MarketScan claims from 2003 to 2010 found no statistically significant difference in one-year adjusted all-cause healthcare costs between the two procedures: $20,407 for myomectomy versus $25,019 for uterine artery embolization (UAE). Single-institution cost studies that drive many online comparisons point in a different direction. Both findings can be true: one measures a broader year of healthcare spending, while the other looks at costs recorded within particular hospitals.

For patients comparing procedures, the useful question is not simply which one has the lower price tag. It is how the facility, professional services, recovery, insurance design, and possibility of future treatment fit together. That is where the financial differences become more concrete, and where a seemingly clear estimate can start to blur.

The Anatomy of Procedural Pricing: Facility vs. Physician Fees

Uterine-sparing fibroid procedures generate two distinct cost streams. The first is the facility charge for the hospital or outpatient center where the procedure takes place. The second is the professional fee paid to the operating physician. They may appear together in a broad estimate, but they are usually separate parts of the bill.

In a Georgetown single-institution analysis, estimated hospital costs were $3,193 for uterine artery embolization versus $5,598 for abdominal myomectomy. Professional physician costs ran in the other direction: $2,220 for the interventional radiologist performing UAE compared with $1,611 for the gynecologic surgeon performing abdominal myomectomy. A Jefferson Medical College hospital accounting dataset showed a similar facility-side gap: $2,707 for UFE versus $5,676 for myomectomy. The institution recorded a net margin of +$57 per UFE patient against a net loss of -$715 per myomectomy patient.

A hospital estimate for myomectomy is not the same number as the surgeon’s bill. The two are billed separately, and their relative costs can move in opposite directions.

The comparison changes depending on which part of the bill is under discussion. Facility costs in these studies favored UFE; physician fees favored myomectomy. Neither comparison, on its own, describes what an individual patient will owe. The final amount depends on the negotiated rates between providers and the insurance plan, the deductible, coinsurance, and whether the patient has already reached an out-of-pocket maximum.

A high-deductible plan can make the timing of care matter as much as the procedure. If a patient has not met the deductible, she may be responsible for a larger share of the negotiated costs early in the year. Once the deductible is met, coinsurance may apply until the plan’s out-of-pocket maximum is reached. A patient whose plan has a fixed copayment for a particular service may face a different calculation. The same procedure can therefore produce different bills for two people at the same facility.

The estimates in hospital accounting studies are also not necessarily the same thing as a patient-facing price quote. They reflect particular institutions, billing practices, and accounting methods. They can help explain why one portion of care costs more than another, but they should not be treated as a current universal price list.

Hidden Financial Variables: Anesthesia, Pathology, and Imaging

The headline procedure cost is rarely the whole bill. Anesthesia, pathology, and imaging can each appear as separate services, with their own provider and insurance arrangements. A useful estimate identifies these components rather than presenting one broad number that leaves the details unclear.

• Anesthesia services. Myomectomy commonly involves general anesthesia, billed by an anesthesiologist or anesthesia group. UFE may involve conscious sedation or monitored anesthesia care, depending on the clinical plan and the patient. The federal No Surprises Act generally protects patients from out-of-network anesthesia bills for covered services at an in-network facility. An anesthesia group’s independent contract with the facility does not, by itself, remove those protections. Billing risk may remain when the Act’s protections do not apply, such as when the facility or service is not covered by the law, or when a patient is treated at an out-of-network facility. Patients can ask the insurer and facility how the planned care will be processed and what protections apply to their circumstances.
• Surgical pathology. Tissue removed during myomectomy is generally sent for histopathologic analysis. Pathology may be billed separately from the surgeon and facility, so it is worth asking whether the estimate includes it and how the plan processes the charge. UFE does not remove fibroid tissue for examination, so this particular line item does not arise in the same way.
• Pre-procedure imaging. Pelvic MRI may be used to map fibroids before either procedure, especially when their number, size, or location affects treatment planning. The imaging facility and the clinician interpreting the scan may bill separately. A patient should confirm whether the scan is included in an estimate, whether prior authorization is required, and whether the imaging location and interpreting provider are in network.

For open abdominal myomectomy, length of stay can also affect the facility bill. Each additional inpatient night adds approximately $2,000 to $4,000 in the accounting figures described in the draft data. That is a substantial swing, although an estimate of extra facility cost is not necessarily the amount a patient will owe. The insurer’s contract, benefit design, and the services billed during the stay all matter.

A practical estimate should make clear what is included and what is not. If the facility estimate covers the operating room but leaves out the surgeon, anesthesia, pathology, or imaging, the patient is looking at a partial figure. That does not mean the estimate is wrong. It means the remaining pieces need to be understood before comparing options.

The Economics of Recovery: Factoring in Indirect Costs and Lost Wages

Direct medical costs tell only part of the financial story. Time away from work, dependent care, transportation, and help at home can shape the real cost of a procedure. These expenses are harder to capture in a hospital estimate, but they may matter more than a modest difference in facility charges for someone paid by the hour or without paid leave.

Myomectomy recovery varies with the surgical approach. The recovery window can range from about two to six weeks. Open abdominal myomectomy often involves the longer period, with restrictions on heavy lifting and full activity lasting roughly four to six weeks. Laparoscopic and robotic approaches generally have shorter recovery windows, often around two to three weeks. Hysteroscopic myomectomy is usually associated with same-day or next-day recovery, though the individual experience depends on the procedure and the patient.

UFE recovery is typically about a week, with many patients returning to desk-based work within five to seven days. Strenuous activity may remain restricted for one to two weeks. Recovery is not identical for everyone, and the return-to-work timeline should be discussed with the treating clinician rather than treated as a guarantee.

For a working patient, time away from work can change the comparison as much as the procedure bill. The number of missed shifts matters alongside the price of the procedure.

The difference in indirect costs may be most pronounced when UFE is compared with open abdominal myomectomy. It can narrow when the comparison is with laparoscopic or robotic myomectomy, since the recovery periods may be closer. That makes the planned surgical approach a financial question as well as a clinical one. Patients considering myomectomy can ask which approach is recommended for their fibroid anatomy and why, then use that specific plan when discussing time off and support at home.

A rough personal estimate does not need to be elaborate. Start with the time away from work that the clinician considers realistic, then consider whether the patient has paid leave, short-term disability, or the option to work remotely. Add likely costs for transportation, childcare, or help with lifting and household tasks. These are not identical for every household, and they should not be folded into a single national estimate. Their value lies in making visible costs that a facility quote will not include.

Long-Term Financial Risks: Reintervention Rates and Age-Specific Outcomes

An upfront cost comparison can miss a second question: whether further treatment may be needed later. A procedure that costs less at the outset can become more expensive over time if symptoms return or another intervention is required. That possibility is not a certainty for an individual patient, but it belongs in a longer-term financial discussion.

A multicenter retrospective cohort of 863 patients tracked secondary fibroid intervention over seven years. Overall secondary intervention rates were 8.9% after UAE and 11.2% after myomectomy, a difference that did not reach statistical significance across the full cohort. The age-stratified analysis showed a different signal: among women aged 30 to 39, UAE patients had a hazard ratio of 3.76 for secondary intervention compared with myomectomy patients in the same age group.

A hazard ratio is a relative measure, not an individual probability. It does not mean that a particular patient has a 3.76-in-10 chance of needing another procedure, nor does it predict what that second intervention would cost. The result does suggest that age may affect how the long-term comparison looks, and it is a reason to ask how the study relates to one’s own circumstances rather than relying on the overall rates alone.

This does not make UFE a clinically inferior procedure for younger women. The choice also depends on symptoms, fibroid anatomy, fertility goals, and surgical candidacy. A 32-year-old planning over a longer horizon may weigh the possibility of future treatment differently from a 48-year-old with a different set of priorities. The financial model is therefore not uniform across age groups, and a single average can conceal meaningful differences.

Long-term planning should also separate the chance of another intervention from the cost of that intervention. A study tracking reintervention does not by itself provide a patient-specific forecast of future spending. Insurance can change, deductibles reset, and the later treatment may not be the same for every patient. The rates help frame a conversation about uncertainty; they do not settle the bill in advance.

Navigating Insurance and Self-Pay Realities for Fibroid Care

For uninsured self-pay patients, fibroid interventions generally fall in a $6,000 to $30,000 range across both procedures, with substantial variation by geographic market, facility type, and surgical approach. Academic medical centers and hospital outpatient departments may be at the upper end, while ambulatory surgery centers may be lower. The lower end of the range may reflect a hysteroscopic or laparoscopic procedure in a lower-cost market; the upper end may reflect open abdominal myomectomy in a major metropolitan hospital. These are broad estimates, not a substitute for a written quote tied to a specific treatment plan.

For commercially insured in-network patients, typical out-of-pocket exposure can run from $2,000 to $7,500, depending on whether the deductible has been met, the plan’s coinsurance, and the out-of-pocket maximum. Patients with high-deductible health plans who have not yet met the deductible may owe more of the negotiated rate at first. Once the deductible is reached, coinsurance may apply until the out-of-pocket maximum is met. The plan’s rules, the services billed, and care received earlier in the year all affect the result.

For either insurance or self-pay, a written estimate is more useful when it separates the expected charges. Patients can ask for the facility estimate and professional fees individually, then clarify whether anesthesia, imaging, pathology, and any anticipated inpatient stay are included. For insured care, the insurer can help confirm network status and explain how the plan applies benefits. For self-pay care, ask what the quote covers and what might change it, including a change in approach or length of stay.

The figures in this table come from single-institution accounting data and retrospective analyses. They are not current quotes, and the facility and professional amounts should not be added together as though they were a personalized estimate. Actual costs depend on the specific facility, clinician, insurance contract, and services rendered.

Four questions can make a cost comparison more useful:

1. What does the facility estimate include? Request the facility and physician estimates separately, and ask which services are still unpriced. The hospital figure may not include the surgeon or interventional radiologist.

2. How will ancillary services be billed? Ask about anesthesia, pre-procedure imaging, and pathology where applicable. Confirm network status with the insurer and clarify how federal billing protections apply to the planned care.

3. Which approach is planned, and why? For myomectomy, whether the recommended approach is open, laparoscopic, robotic, or hysteroscopic affects both direct cost and recovery. The answer should be tied to the patient’s fibroid anatomy, not simply to a general price comparison.

4. What costs fall outside the medical bill? Consider time away from work, transport, dependent care, and support during recovery. A shorter recovery may reduce those costs, but the personal effect depends on work arrangements and household needs.

A scheduling office’s estimate is a starting point, not a complete forecast. Cash prices can vary by location and provider, and insured patients may owe a different amount from the listed charge because their plan uses negotiated rates. A clear comparison identifies what is known, what is still uncertain, and which assumptions could change the total.

The Bottom Line

UFE does not have a uniformly lower cost than myomectomy. Hospital accounting data show a facility-cost advantage for UFE and a physician-cost disadvantage, while one-year commercial claims data found no statistically significant difference in total adjusted costs. The procedure that reduces a patient’s financial exposure depends on insurance structure, the specific surgical approach, recovery needs, and the possibility of future treatment.

For younger patients, the age-stratified reintervention finding may matter when considering care over a longer period, but a hazard ratio is not a personal prediction. For someone weighing laparoscopic myomectomy against UFE, the recovery and direct-cost differences may be narrower than in a comparison with open surgery. For a patient whose work or caregiving responsibilities make time away especially costly, recovery can weigh heavily even when the medical bill looks lower.

The useful estimate is the one that follows the care from the first scan through recovery: facility, physician, anesthesia, pathology where relevant, imaging, and time away from work. Once those pieces are visible, the comparison becomes less about a single advertised price and more about the costs that are likely to matter for that patient.